Arterial Network learned that Cyrcadia Asia, a startup for breast cancer intelligence testing equipment, announced that it has received $3.8 million (about 25 million yuan) of Pre-A round of financing, invested by iFlytek, a well-known artificial intelligence technology listed company. Other Asian investment funds and private investors have also joined. This round of financing is mainly used for propulsion Cyrcadia Asia's health care plan, support its product development completed by the end of 2018 and put into Hong Kong and other ASEAN markets. Founded in Hong Kong in 2017, Cyrcadia Asia develops smart wearable bra inserts to provide accurate early breast cancer detection. The company has signed a strategic licensing and cooperation agreement with Cyrcadia Inc. to enable the manufacture and commercialization of Cyrcadia's breast cancer testing products and its launch in the Asian market. It is reported that the product will be launched in Nypro's Shanghai plant in the summer of 2018. Cyrcadia's wearable device is a revolutionary sensor patch that fits under a female bra and is worn for two hours a month, allowing women to monitor their breast health through their mobile app. The technology uses data cloud-based artificial intelligence to monitor clinically documented changes in the metabolic function of the mammary gland associated with cancer, which has particular advantages in Asia. Because of the low participation rate of female screening in Asia, the incidence of cancer is increasing, and the breast tissue of most Asian women is dense, and the accuracy of judgment using traditional imaging techniques is poor. After more than a decade of research, Cyrcadia Asia has been launched in the Asian market. The company has also conducted extensive tests in the United States and has now passed the US FDA 510k license. The technology is also widely acclaimed, including two Cannes International Creative Awards for the Innovation and Women's Empowerment and the Clio International Advertising Awards. In addition, the technology appears in the documentary "Detected" produced by Ironbound Films and launched on Amazon Prime. Investor Keda Xunfei was established in 1999 and is the largest listed company in artificial intelligence technology in the Asia Pacific region. It was listed on the Shenzhen Stock Exchange in 2008. The company has been committed to speech intelligence research, exploring the most natural form of human-computer interaction, and has leading edge in the fields of intelligent speech and artificial intelligence technologies such as speech synthesis, speech recognition, speech evaluation, and natural language processing. The medical department of HKUST is established in 2016 and is led by Dr. Tao Xiaodong, a senior technical expert at Philips and GE Healthcare. Dr. Tao Xiaodong, General Manager of Keda Xunfei Smart Medical Division has extensive experience in the fields of medical imaging and computer-aided diagnosis. With the completion of this financing, HKUST will further promote its health care plan, and Dr. Tao Xiaodong also joined the board of Cyrcadia Asia. In the past two years, Keda News has also made rapid progress in medical + artificial intelligence. In November 2017, the company's “Little Doctor†artificial intelligence robot successfully passed the national medical examination, and the Chinese doctor qualification examination scored 456 points, 96 points higher than the qualified standard. In addition, HKUST is currently deploying artificial intelligence services in more than 50 hospitals in Anhui Province to provide diagnostics, treatment and interpretation of medical images including breast imaging. Dr. Tao Xiaodong commented on this investment: "We are very pleased to play a leading role in Cyrcadia's technology development and market launch. iFlytek has already practiced the power of artificial intelligence in the medical field, and Cyrcadia's technology uses metabolic changes to detect Diseases can overcome and compensate for the many shortcomings of current imaging technology and manual interpretation. We are also pleased with Cyrcadia's consumer wearable device technology, which provides women with the convenience and possibility to monitor their health in real time. With the growth of the group, it is likely to become the world's largest database of breast health and breast cancer, and we hope that in the near future we will be able to make significant contributions to the research, prevention and treatment of this disease." Mr. Rob Royea, CEO and Chairman of Cyrcadia Asia, said: “We are very pleased that iFlytek can be our investor and a strategic partner in the field of artificial intelligence and medical. The technology of Cyrcadia Asia will enable women to compare with existing ones. Screening methods provide a more comfortable and convenient way to monitor their breast health and maximize life-saving by detecting the likelihood of cancer at an early stage, as the cancer thus diagnosed will be easier to treat and usually does not require chemotherapy. iFlytek's partnership opens many avenues for data cloud-based deployment of artificial intelligence applications that can significantly improve breast cancer diagnosis for existing clinicians." In addition to investing, HKUST and Cyrcadia Asia will jointly explore how to integrate Cyrcadia's technology into the medical products of HKUST. Cyrcadia Asia will launch Series A fundraising in the third quarter of 2018 to fund its further expansion beyond the market. Small Safe,Smart Safe,Electronic Safe,Portable Safe Box Hebei Yingbo Safe Boxes Co.,Ltd , https://www.ybsafebox.com